Functionally biased signalling properties of 7TM receptors – opportunities for drug development for the ghrelin receptor
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The ghrelin receptor is a 7 transmembrane (7TM) receptor involved in a variety of physiological functions including growth hormone secretion, increased food intake and fat accumulation as well as modulation of reward and cognitive functions. Because of its important role in metabolism and energy expenditure, the ghrelin receptor has become an important therapeutic target for drug design and the development of anti‐obesity compounds. However, none of the compounds developed so far have been approved for commercial use. Interestingly, the ghrelin receptor is able to signal through several different signalling pathways including G α q,G αi/o,G α 12/13 and arrestin recruitment. These multiple signalling pathways allow for functionally biased signalling, where one signalling pathway may be favoured over another either by selective ligands or through mutations in the receptor. In the present review, we have described how ligands and mutations in the 7TM receptor may bias the receptors to favour either one G‐protein over another or to promote G‐protein independent signalling pathways rather than G–protein‐dependent pathways. For the ghrelin receptor, both agonist and inverse agonists have been demonstrated to signal more strongly through the G α q‐coupled pathway than the G α 12/13‐coupled pathway. Similarly a ligand that promotes G α q coupling over G α i coupling has been described and it has been suggested that several different active conformations of the receptor may exist dependent on the properties of the agonist. Importantly, ligands with such biased signalling properties may allow the development of drugs that selectively modulate only the therapeutically relevant physiological functions, thereby decreasing the risk of side effects. Linked Articles: This article is part of a themed section on Neuropeptides. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.170.issue‐7
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009 · cited 4×
“More recently crystal structures of the β2-adrenoceptor bound to either an agonist or an inverse agonist, as well as the receptor in complex with the G-protein have been resolved (Rasmussen et al., 2007; 2011).”
BackgroundInfluentialA preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Plasma levels of ghrelin increase before a meal and subsequently decrease after energy intake in human subjects, suggesting ghrelin is a meal initiator or meal preparator (Cummings et al., 2001).”
BackgroundGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 1×
“…protein 2; VTA, ventral tegmental area; WT, wild type Introduction to ghrelin receptor physiology The ghrelin receptor, previously known as the growth hormone secretagogue (GHS) receptor 1a (for receptor nomenclature see Alexander et al., 2011), is the receptor for the anabolic hormone ghrelin.”
BackgroundBiological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187 · cited 1×
“In addition it can also modulate behaviour and mood (van der Lely et al., 2004; Dickson et al., 2011; Figure 1).”
BackgroundType-Specific Regulation of Adenylyl Cyclase by G Protein βγ Subunits
Tang, W.-J., & Gilman, A. G. (1991) · Science · doi:10.1126/science.1962211 · Cited by 1,091 · cited 2×
“…pathways such as calcium release (Stehno-Bittel et al., 1995), PLB, adenylate cyclase, but also MAPK, nucleic histone deacetylase 5 and adipocyte enhancerbinding protein 1 among others (Tang and Gilman, 1991; Crespo et al., 1994; Zhang et al., 1996; Park et al., 1999; Spiegelberg and Hamm, 2005).”
BackgroundAbizaid, A., Liu, Z.-W., Andrews, Z. B., Shanabrough, M., Borok, E., Elsworth, J. D., Roth, R. H., Sleeman, M. W., Picciotto, M. R., Tschöp, M. H., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29867 · Cited by 984 · cited 1×
“This effect was reversed by infusion of a ghrelin receptor antagonist into the VTA, which reduced ghrelin-induced feeding behaviour (Abizaid et al., 2006).”
BackgroundTrends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · cited 1×
“Importantly a large percentage of drugs on the market targets the 7TM receptor superfamily, including some anti-histamines and β-blockers (Rask-Andersen et al., 2011).”
BackgroundGhrelin controls hippocampal spine synapse density and memory performance
Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., Gaskin, F. S., Nonaka, N., Jaeger, L. B., Banks, W. A., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1656 · Cited by 828 · cited 1×
“It was also shown that ghrelin promotes dendritic spine formation and contributes to long-term potentiation, consistent with its involvement in memory retention (Diano et al., 2006).”
BackgroundUCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals
Andrews, Z. B., Liu, Z.-W., Walllingford, N., Erion, D. M., Borok, E., Friedman, J. M., Tschöp, M. H., Shanabrough, M., Cline, G., Shulman, G. I., et al. (2008) · Nature · doi:10.1038/nature07181 · Cited by 710
High constitutive signaling of the ghrelin receptor–identification of a potent inverse agonist
Holst, B., Cygankiewicz, A., Jensen, T. H., Ankersen, M., & Schwartz, T. W. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0069 · Cited by 515 · cited 3×
“) of the substance P analogue, a series of inverse agonists has been developed (Holst et al., 2003).”
BackgroundSelf-citationMUNDAY, M. R., CAMPBELL, D. G., CARLING, D., & HARDIE, D. G. (1988) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1988.tb14201.x · Cited by 308 · cited 1×
“The phosphorylation of AMPK leads to the inactivation of acetyl-CoA carboxylase (Munday et al., 1988), preventing malonyl-CoA formation, the substrate of fatty acid synthase (FAS).”
BackgroundThe Central Sirtuin 1/p53 Pathway Is Essential for the Orexigenic Action of Ghrelin
Velásquez, D. A., Martínez, G., Romero, A., Vázquez, M. J., Boit, K. D., Dopeso-Reyes, I. G., López, M., Vidal, A., Nogueiras, R., & Diéguez, C. (2011) · Diabetes · doi:10.2337/db10-0802 · Cited by 161 · cited 2×
“The dissociation between the pathways modulating GH secretion and food intake has also been shown in in vivo studies where a specific inhibitor of the intracellular enzyme SIRT1 selectively blocked the ghrelin-induced food intake, but did not affect GH secretion (Velasquez et al., 2011).”
BackgroundLage, R., Vázquez, M. J., Varela, L., Saha, A. K., Vidal‐Puig, A., Nogueiras, R., Diéguez, C., & López, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150672 · Cited by 123
The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture
Bach, M. A., Rockwood, K., Zetterberg, C., Thamsborg, G., Hébert, R., Devogelaer, J., Christiansen, J. S., Rizzoli, R., Ochsner, J. L., Beisaw, N., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52156.x · Cited by 83 · cited 1×
“However, the results were not good enough to support further clinical development with GH secretion as primary focus (Murphy et al., 2001; Bach et al., 2004).”
Background
Cited by
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
GPCR Dynamics: Structures in Motion
Latorraca, N. R., Venkatakrishnan, A. J., & Dror, R. O. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00177 · Cited by 835
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 279
Lorton, D., & Bellinger, D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16035635 · Cited by 221
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Metadata
- Authors
- Sivertsen, B., Holliday, N., Madsen, A. N., & Holst, B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-11-14
- Volume
- 170
- Issue
- 7
- Pages
- 1349-1362
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1580261433
- Cited by
- 64
- References
- 14
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.